Ubrogepant for the treatment of migraine attacks during the prodrome: a phase 3, multicentre, randomised, double-blind, placebo-controlled, crossover trial in the USA

Authors: David W. Dodick, Peter J. Goadsby, Todd J. Schwedt, Richard B. Lipton, Chengcheng Liu, Kaifeng Lu, Sung Yun Yu, Lawrence Severt, Michelle Finnegan, Joel M. Trugman - The Lancet 2023 cited by 85